On Wednesday, POLITICO reported that GOP pollster Tony Fabrizio, a pollster for
President Trump’s campaign, “showed new polling to members of the Republican
Study Committee” urging them to “pivot to reducing drug prices.” During the
meeting, Fabrizio “advised a group of House Republicans…[to] focus on reducing
drug prices.”





 

December 5, 2025



TOPLINE



On Wednesday, POLITICO reported
<[link removed]>
that GOP pollster Tony Fabrizio, a pollster for President Trump’s campaign,
“showed new polling to members of the Republican Study Committee” urging them
to “pivot to reducing drug prices.” During the meeting, Fabrizio “advised a
group of House Republicans…[to] focus on reducing drug prices.”



Earlier this year, in February, CSRxP released the results
<[link removed]>
of public opinion research conducted by Fabrizio showing that American voters
overwhelmingly hold Big Pharma responsible for high prescription drug prices
and support market-based solutions to lower prices by holding big drug
companies accountable, including for gaming the U.S. patent system to block
competition.



“Results from the new national survey of voters…show broad and overwhelmingly
bipartisan support for policy solutions to lower the cost of prescription drugs
by addressing pricing and anti-competitive practices from drug companies,”
Fabrizio and fellow pollster Bob Ward wrote in amemo
<[link removed]>
on their findings. “The electorate, including equal numbers of Trump and
Harris Voters, holds intensely unfavorable views of drug companies. By wide
margins, voters are very concerned about the cost of Rx drugs, hold drug
companies responsible, and clearly identify drug company profits as the driver
of high drug costs.” Read more on the public opinion research conducted by
Fabrizio Ward in FebruaryHERE
<[link removed]>
.



Also, in case you missed it, on Monday, the U.S. House of Representatives
passed theGive Kids a Chance Act of 2025 (H.R. 1262
<[link removed]>), which
includes bipartisan provisions from theIncreasing Access to Generic Drug
Applications Act (H.R. 1843
<[link removed]>
) to improve transparency in generic drug applications.



This bipartisan, market-based solution would reform the Q1/Q2 sameness
requirements from the U.S. Food and Drug Administration (FDA) that Big Pharma
abuses to extend exclusivity, promoting a more efficient and streamlined
generic drug approval process. These reforms were adopted as an amendment
during the House Energy and Commerce Committee markup in September, where they
advanced unanimously by a vote of 47-0. Read more on H.R.1843HERE
<[link removed]> and
read more on Q1/Q2 reformsHERE
<[link removed]>
.



QUOTES OF THE WEEK



“CSRxP applauds the House for advancing bipartisan, market-based reforms to
increase transparency in generic drug applications and help stop Big Pharma
from exploiting Q1/Q2 requirements to delay competition and keep drug prices
high. We urge the Senate to swiftly pass this commonsense solution to help
foster greater competition from more affordable alternatives to high-priced
brand name drugs.”



CSRxP executive director Lauren Aronson
<[link removed]>



DATA POINT YOU SHOULD KNOW



82 Percent



According to a survey
<[link removed]>
conducted by Tony Fabrizio and Bob Ward earlier this year, 82 percent of
voters support reforming patent laws to prevent drug companies from abusing the
system to extend monopolies on drugs longer than intended and block lower cost
generic drugs and biosimilars from the market.



TWEETS OF THE WEEK



@bmj_latest <[link removed]>: “Next
generation weight loss drugs are prohibitively expensive for many in the US who
would benefit from taking them—and may remain so, thanks to the phenomenon of
patent thickets. Paige Huffman reports
[link removed]

<[link removed]>
”



@Runaway_Rx <[link removed]>: “Big
Pharma loves gaming the patent system to keep its prices sky-high. #BigPharma’s
three big plays – The Fresh Coat, The Delay Game, and The Thicket Trap – keep
drug prices high while patients pay more money. Shouldn’t that be considered
foul play? Take a look at their Patent Playbook here:[link removed]
<[link removed]> #TheProblemIsThePrice”



ROAD TO RECOVERY



STAT News: Four In Five Americans Support Patent Reform To Lower Drug Prices,
New Survey Finds
<[link removed]>



A new national survey reveals overwhelming bipartisan support for overhauling
the patent system to address soaring prescription drug costs in the United
States, with 80% of Americans backing such reforms. The survey of 726 American
adults, commissioned by the Initiative for Medicines, Access and Knowledge
(I-MAK) and conducted by Franklin & Marshall College’s Center for Opinion
Research, found consensus across party lines on the need to address high
prescription drug prices through patent reform. The findings come as Americans
grapple with difficult choices about their medications due to cost. Among the
71% of adults who reported taking prescription drugs in the past year, nearly
one in three said they did not fill at least one prescription because they
couldn’t afford it.



Inside Health Policy: Researchers: More USPTO Action Needed To Curb Drug IP
Abuses
<[link removed]>



Policymakers must act to strengthen the U.S. Patent and Trademark Office’s
examination processes and prevent brand drug companies’ ability to receive
multiple anticompetitive patients, researchers with the University of Alabama
urged in an article published this month in the Journal of the American Medical
Association (JAMA). Authors Sean Tu and Ana Santos Rutschman argue that in
addition to stronger examination procedures, courts should consider deterring
anticompetitive conduct by requiring repayment of profits from gained through
anticompetitive pricing strategies, a remedy they say is being applied in some
foreign jurisdictions.



PHARMA’S POOR PROGNOSIS



The BMJ: Will Americans Ever Be Able To Afford Weight Loss Drugs?
<[link removed]>



In the US, these drugs are still too expensive for many people who would
benefit from them. Hopes that lower priced generics will be available after the
expiry of patents may be confounded by a US phenomenon that has kept other
groundbreaking drugs prohibitively expensive: patent thickets… “Patent thickets
are inherently egregious, but in the case of GLP-1 drugs, they’re particularly
egregious because they’re transparently relying on patents that have nothing to
do with clinical effectiveness,” says Jon Conradi, a spokesperson for the
Campaign for Sustainable Rx Pricing.



The Tennessean: Opinion: Patent Abuse And How It Keeps Life-Saving Drugs Out
Of Reach
<[link removed]>



My husband has fought leukemia for more than 10 years. As part of his therapy,
he takes a drug that can cost more than $30,000 a month and is so hard on the
body that one doctor told us he wouldn’t give it to a farm animal.
Unfortunately, it’s the best one we have, in no small part because Big Pharma’s
patent abuse has kept cheaper and/or less harmful alternatives off the market.



###



























Copyright © 2019 Campaign for Sustainable Rx Pricing
Our address is 1341 G St NW, #1100, Washington, DC xxxxxx


This email was sent to [email protected]. To unsubscribe please click
here.
<[link removed]>